A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Celecoxib (Primary) ; Eflornithine
- Indications Colorectal cancer; Familial adenomatous polyposis
- Focus Therapeutic Use
- 08 Sep 2020 Status changed from discontinued to completed.
- 12 Jun 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 22 May 2012 Results presented at Digestive Disease Week 2012.